U.S. markets open in 6 hours 14 minutes
  • S&P Futures

    3,922.50
    +18.75 (+0.48%)
     
  • Dow Futures

    31,563.00
    +142.00 (+0.45%)
     
  • Nasdaq Futures

    12,109.00
    +68.50 (+0.57%)
     
  • Russell 2000 Futures

    1,782.30
    +12.50 (+0.71%)
     
  • Crude Oil

    111.36
    +1.79 (+1.63%)
     
  • Gold

    1,828.30
    +3.50 (+0.19%)
     
  • Silver

    21.29
    +0.12 (+0.58%)
     
  • EUR/USD

    1.0586
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    3.1940
    0.0000 (0.00%)
     
  • Vix

    26.95
    -0.28 (-1.03%)
     
  • GBP/USD

    1.2271
    +0.0001 (+0.01%)
     
  • USD/JPY

    135.7470
    +0.3010 (+0.22%)
     
  • BTC-USD

    20,903.17
    -413.30 (-1.94%)
     
  • CMC Crypto 200

    455.77
    -6.03 (-1.31%)
     
  • FTSE 100

    7,323.97
    +65.65 (+0.90%)
     
  • Nikkei 225

    27,049.47
    +178.20 (+0.66%)
     

FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The FDA has granted Fast Track designation to Antares Pharma Inc's (NASDAQ: ATRS) for ATRS-1902 for adrenal crisis rescue.

  • The development program for ATRS-1902 supports a proposed indication of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using Vai proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone.

  • The agency has also granted the Fast Track tag to Celcuity Inc's (NASDAQ: CELC) gedatolisib for HR+/HER2- metastatic breast cancer after progression on CDK4/6 therapy.

  • Celcuity remains on track to obtain feedback from the FDA to finalize the design and protocol of its Phase 3 trial in Q1 of 2022. Site identification and feasibility activities for the Phase 3 clinical trial are ongoing.

  • The FDA has given Fast Track status to Celularity Inc's (NASDAQ: CELU) CYNK-101, an investigational genetically modified NK cell therapy.

  • CYNK-101 is being developed in combination with standard chemotherapy, trastuzumab, and pembrolizumab in patients in first-line locally advanced unresectable or metastatic HER2/neu positive gastric or gastroesophageal junction adenocarcinoma.

  • Price Action: ATRS shares are down 2.38% at $3.49, CELU stock is down 7.00% at $3.85, CELC shares are up 4.51% at $12.05 during the market session on the last check Tuesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.